ArticleKidney international reports2022
Atypical Antiglomerular Basement Membrane Nephritis Following Immune Checkpoint Inhibitor.
Article in Kidney international reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 16 citations in OpenAlex.
- ANCA-negative pauci-immune crescentic glomerulonephritis associated with nivolumab in lung cancer.CEN case reports · 2026Article
- Anti-GBM Disease Following Ovarian Mesonephric-Like Adenocarcinoma: A Unique Insight Into Paraneoplastic Autoimmunity.Kidney medicine · 2025Article
- Durvalumab-Associated Crescentic Glomerulonephritis With IgA Vasculitis-Like Features.Kidney international reports · 2025Article
- Two acute kidney injury episodes after ICI therapy: a case report.CEN case reports · 2024Article
- Pembrolizumab-Induced Anti-GBM Glomerulonephritis: A Case Report.Kidney medicine · 2023Article
- Atypical Anti-Glomerular Basement Membrane Disease.Kidney international reports · 2023Review
- Concomitant Anti-GBM Glomerulonephritis and Acute Interstitial Nephritis Following Programmed Death Receptor-1 Blockade With Nivolumab.Kidney international reports · 2022Article
- Anti-Glomerular Basement Membrane Disease in Association with Pembrolizumab Treated with Rituximab in Addition to Standard Care: A Case Report.Glomerular diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.